← All companies ← BV Manual BW → ← BSX Medical Devices & Equipment BWAY →
BVS, Bioventus Inc.
We are a global medical device company focused on helping patients recover and live life to the fullest by relieving pain and addressing musculoskeletal challenges through a diverse portfolio of high-quality, innovative, and clinically-proven solutions.
Our portfolio of products is comprised of five patient-focused areas, grouped into three businesses based on clinical use: (i) Pain Treatments & PRP ("Pain Treatments"), (ii) Surgical Solutions and (iii) Restorative Therapies.
Knee Osteoarthritis ("KOA") : Our product portfolio includes a range of intra-articular, hyaluronic acid ("HA") injections that help relieve patient discomfort and improve quality of life.
The business
What it sells, where the money comes from, the kind of company it is.
Next report By 11/5 · the 10-Q for the quarter ended late September · due within 40 days of period end · has filed ~39 days after · the wire records it on arrival
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
- What moves the needle
- Gross margin has run about 68% and operating margin about 2.8% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The operating margin has swung widely — from −33% to 10% — on a steadier 68% gross margin, so what moves it sits below the gross line, in operating spend and one-off charges more than in the cost of the product itself. Inventory runs near 14% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the installed base and what follows it. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median −3%, above 15% in 0 of 5 years). By owner earnings: roughly 7% of revenue reaches owners as cash, consistently. The cycle and the balance sheet decide this one; the worst year tells more than the median, and the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2019–2025
realized figures from each filing · older years to the left| 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMJun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| $340M | $321M | $431M | $512M | $512M | $573M | $568M | $582M | RevenueRevenue |
| $249M | $234M | $303M | $331M | $328M | $388M | $388M | $399M | Gross profitGross prof. |
| 73% | 73% | 70% | 65% | 64% | 68% | 68% | 69% | Gross marginGross mgn |
| 58% | 60% | 59% | 65% | 59% | 60% | 55% | 55% | SG&A / revenueSG&A/rev |
| 3% | 3% | 4% | 5% | 3% | 2% | 2% | 2% | R&D / revenueR&D/rev |
| $31M | $21M | $12M | ($167M) | ($82M) | ($15M) | $54M | $58M | Operating incomeOp. inc. |
| 9.2% | 6.6% | 2.8% | −32.7% | −16.0% | −2.7% | 9.5% | 10.0% | Operating marginOp. mgn |
| $10M | $16M | $9M | ($189M) | ($121M) | ($52M) | $26M | — | Pretax incomePretax |
| $7M | $16M | $19M | ($159M) | ($156M) | ($36M) | $23M | $54M | Net incomeNet inc. |
| 16% | 7% | — | — | — | — | -6% | — | Effective tax rateTax rate |
| Cash flow & returns | ||||||||
| $41M | $72M | $23M | ($14M) | $15M | $39M | $75M | $97M | Operating cash flowOp. cash |
| $30M | $29M | $35M | $55M | $57M | $50M | $47M | $45M | Depreciation & amortizationD&A |
| $4M | $27M | ($51M) | $72M | $111M | $12M | ($8M) | ($18M) | Working capital & otherWC & other |
| $2M | $17M | $14M | $1M | $7M | $1M | $3M | $3M | CapexCapex |
| 0.7% | 5.2% | 3.1% | 0.3% | 1.4% | 0.2% | 0.5% | 0.4% | Capex / revenueCapex/rev |
| $38M | $55M | $9M | ($15M) | $8M | $38M | $72M | $94M | Owner earningsOwner earn. |
| 11.3% | 17.2% | 2.2% | −2.9% | 1.6% | 6.6% | 12.7% | 16.2% | Owner earnings marginOE mgn |
| $38M | $55M | $9M | ($15M) | $8M | $38M | $72M | $94M | Free cash flowFCF |
| 11.3% | 17.2% | 2.2% | −2.9% | 1.6% | 6.6% | 12.7% | 16.2% | Free cash flow marginFCF mgn |
| $0 | $0 | $263M | — | — | — | — | $368M | AcquisitionsAcquis. |
| ($8M) | ($21M) | ($284M) | ($116M) | $16M | $23M | ($3M) | — | Investing cash flowInv. cash |
| ($11M) | ($30M) | $273M | $62M | ($27M) | ($55M) | ($62M) | — | Financing cash flowFin. cash |
| ($104K) | $589K | ($228K) | $521K | $629K | ($3M) | $371K | — | Exchange-rate effectFX |
| $22M | $22M | $12M | ($67M) | $5M | $5M | $10M | — | Change in cashΔ cash |
| — | — | 2% | -19% | -12% | -3% | 13% | 13% | ROICROIC |
| — | — | 4% | -49% | -90% | -24% | 12% | 24% | Return on equityROE |
| — | — | 4% | −49% | −90% | −24% | 12% | 24% | Retained to equityRetained/eq |
| Balance sheet | ||||||||
| $65M | $87M | $44M | $30M | $37M | $42M | $51M | $29M | Cash & investmentsCash+inv |
| — | $88M | $125M | $136M | $123M | $127M | $128M | $138M | ReceivablesReceiv. |
| — | $29M | $62M | $85M | $91M | $92M | $82M | $80M | InventoryInvent. |
| — | $4M | $17M | $37M | $23M | $24M | $11M | $20M | Accounts payablePayables |
| — | $113M | $170M | $184M | $191M | $196M | $200M | $198M | Operating working capitalOper. WC |
| — | $212M | $263M | $273M | $268M | $276M | $273M | $258M | Current assetsCur. assets |
| — | $123M | $181M | $304M | $175M | $210M | $160M | $152M | Current liabilitiesCur. liab. |
| — | 1.7× | 1.5× | 0.9× | 1.5× | 1.3× | 1.7× | 1.7× | Current ratioCurr. ratio |
| — | $7M | $23M | $28M | $37M | $27M | $22M | — | Net PP&ENet PP&E |
| — | $50M | $148M | $7M | $7M | $7M | $7M | $7M | GoodwillGoodwill |
| — | $494M | $1.2B | $1.4B | $811M | $728M | $684M | $673M | Total assetsAssets |
| — | $188M | $358M | $418M | $395M | $336M | $294M | $248M | Total debtDebt |
| — | $102M | $314M | $388M | $358M | $294M | $243M | $219M | Net debt / (cash)Net debt |
| — | — | $692M | $960M | $590M | $542M | $455M | — | Total liabilitiesTotal liab. |
| — | — | $75M | $87M | $48M | $38M | $44M | — | Noncontrolling interestsNCI |
| — | — | $459M | $325M | $174M | $148M | $184M | $228M | Shareholders’ equityEquity |
| 0.0% | 0.0% | 4.6% | 3.4% | 0.5% | 2.3% | 2.2% | 2.6% | Stock comp / revenueSBC/rev |
| Per share | ||||||||
| — | — | 45.5M | 61.4M | 62.6M | 64.5M | 68.9M | 70.4M | Shares out (diluted)Shares |
| — | — | $9.48 | $8.34 | $8.18 | $8.88 | $8.24 | $8.26 | Revenue / shareRev/sh |
| — | — | $0.43 | $-2.59 | $-2.49 | $-0.56 | $0.33 | $0.77 | EPS (diluted)EPS |
| — | — | $0.21 | $-0.24 | $0.13 | $0.59 | $1.05 | $1.34 | Owner earnings / shareOE/sh |
| — | — | $0.21 | $-0.24 | $0.13 | $0.59 | $1.05 | $1.34 | Free cash flow / shareFCF/sh |
| — | — | $0.30 | $0.02 | $0.12 | $0.02 | $0.04 | $0.04 | Cap. spending / shareCapex/sh |
| — | — | $10.09 | $5.30 | $2.77 | $2.29 | $2.67 | $3.24 | Book value / shareBVPS |
| 6-yr | 5-yr | |
|---|---|---|
| Revenue / share | −3.4%/yr (4-yr) | −3.4%/yr (4-yr) |
| Owner earnings / share | +49.7%/yr (4-yr) | +49.7%/yr (4-yr) |
| EPS | −6.2%/yr (4-yr) | −6.2%/yr (4-yr) |
| Capital spending / share | −40.5%/yr (4-yr) | −40.5%/yr (4-yr) |
| Book value / share | −28.3%/yr (4-yr) | −28.3%/yr (4-yr) |
The year, in the company's words
the filing →Verbatim from the 10-K's management discussion. Each sentence is shown only because its subject, direction, and stated figures check out against the filed numbers on this page. The words are the company's; the arithmetic is the record's.
- International-0.7%
“International Net sales decreased $0.5 million, or 0.7%, primarily due to the divestiture of the Advanced Rehabilitation Business, which contributed $7.3 million in net sales during the prior year.”
✓ figure matches the filed record
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedBeyond op. cashEach year's outlays against its operating cash: the mix, and how it drifts. The hatched cap is spending beyond that year's operating cash — financed from the balance sheet or borrowing, not operations.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned $23M of profit into $72M of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | $23M | ($36M) | ($156M) | ($159M) | $19M |
| Depreciation & amortizationnon-cash charge added back | +$47M | +$50M | +$57M | +$55M | +$35M |
| Stock-based compensationreal costnon-cash, but a real cost | +$13M | +$13M | +$3M | +$18M | +$20M |
| Working capital & othertiming of cash in and out, other non-cash items | −$8M | +$12M | +$111M | +$72M | −$51M |
| Cash from operations | $75M | $39M | $15M | ($14M) | $23M |
| Capital expenditurecash put back in to keep running and to grow | −$3M | −$1M | −$7M | −$1M | −$14M |
| Owner earnings | $72M | $38M | $8M | ($15M) | $9M |
| Owner-earnings marginowner earnings ÷ revenue | 13% | 7% | 2% | -3% | 2% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $13M), owner earnings is nearer $59M.
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- Interest expense not tagged in the data
What this means
No usable interest-expense line was tagged in the filing data, but the balance sheet carries real net debt — so the interest burden here is unknown, not absent. Read the debt on the net-debt check below.
- How heavy is the debt, net of cash? $243M · 4.5× operating profitHeavy net debtCash $51M − debt $294M
What this means
Netting $51M of cash and short-term investments against $294M of debt leaves $243M owed, about 4.5× a year's operating profit (5.4× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 82 + DIO 167 − DPO 22 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Below average through the cycle5-yr median, range -19%–13%; 13% latest = NOPAT $54M ÷ invested capital $427MIndustry peers: median -8%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 5 years (it ran 13% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Solid through the cycle7-yr median margin, range -3%–17%; latest $72M = operating cash $75M − maintenance capex $3MIndustry peers: median -5%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 13% of revenue this year, a 7% median across 7 years. Treating stock comp as the real expense it is (less $13M of SBC) leaves $59M.
- Cash-backedCash from ops $75M ÷ net income $23M
What this means
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 0.05×HarvestingCapex $3M ÷ depreciation & amortization as filed $47M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
The promise and the pay packet
- Is the buyback buying ownership, or mopping up? 2.2%The count is risingStock compensation $13M (fiscal 2025), 2.2% of revenue · no repurchases · diluted shares +12.3% since 2022
What this means
Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.
Graham’s defensive tests · 0 of 5 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $568M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity NearCurrent ratio ≥ 2× · 1.70×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt MissDebt ≤ working capital · $294M vs $112M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (7-yr record) · 3 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record —Uninterrupted dividends · no dividend line tagged in the data
What this means
An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.
- Earnings growth MissEarnings +33% over the record · −498%
What this means
At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.84/share (latest year $0.34), the averaged base the calculator's gate runs on, and book value is $2.72/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2019–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 4 of 7
What this means
Lost money in 3 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 0 of 5 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 6% → −3% (3-yr avg ends)
In the filing’s words The margin has held, but the filing names price competition — the pressure is present even where the margin has absorbed it so far.
What this means
The recent-years average (−3%) sits below the early years (6%), but the latest year (10%) is back near the early level: a cyclical trough dragging the window down, not a one-way slide. The through-cycle median is 3% — read it across the cycle, not on the dip.
- Reinvestment, incremental ROIC returns capital
What this means
The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.
- Owner earnings growth +3%/yr
What this means
Owner earnings grew about 3% a year over the record.
- Worst year 2022 · −32.7% op. margin
What this means
Operations went underwater in 2022, understand why before trusting the good years.
- Share count +7.2%/yr
What this means
The share count is rising, dilution works against you on a per-share basis.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Jun 27, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$29M
- Receivables$138M
- Inventory$80M
- Other current assets$10M
- Debt due within a year$19M
- Accounts payable$20M
- Other current liabilities$114M
From the company's latest filing.
How the cash was used, 2019–2025
Over the record, the business generated $251M of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.
- Reinvested$45M · 18%
- Retained (debt / cash)$206M · 82%
- Net change in share count54.9%
The diluted count rose from 45M to 70M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.
- Dividend record—
No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Acquisitions & goodwill
from the balance sheet & the 7-year cash-flow recordGoodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.
None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.
Beside that spending sits $268M of cumulative amortization of acquired intangibles charged against earnings since fiscal 2019 — the purchase price of past deals, expensed over time.
Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and amortization summed across the company's full tagged history, write-downs across the 7-year record, from the company's own filings.
Management, ownership & pay
read the proxy →From the proxy: how much of the business the people running it own, and how they are paid.
- Insider ownership33.5%
The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.
- Stock-based compensation$13M
The slice of the business handed to employees in shares in fiscal 2025, 2.2% of revenue, equal to 23.5% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
What an owner would ask, FY2025
read the 10-K →- Which reported numbers are a judgment call?Management names Revenue recognition, Income taxes, Acquisitions, Stock compensation as critical estimates
each rests partly on management's judgment; the filing's note sets out the assumptionsverify →
The questions the record and the charts do not answer on their own; each carries the figure and the place to look.
Peers, Medical Devices & Equipment
The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.
| Company | Revenuelatest FY, USD | Gross marginmedian over the record | Op. marginmedian over the record | ROICmedian over the record | Owner earn. marginmedian over the record |
|---|---|---|---|---|---|
| ATECAlphatec Holdings | $764M | 68% | -30.2% | -47% | -31% |
| IRTCiRhythm Technologies | $747M | 70% | -25.5% | -29% | -13% |
| NVCRNovoCure | $655M | 75% | -19.4% | -23% | -5% |
| BVSBioventus Inc. | $568M | 68% | 2.8% | -3% | 7% |
| ATRCAtriCure | $535M | 74% | -10.8% | -8% | -8% |
| GKOSGlaukos Corporation | $507M | 76% | -25.2% | -8% | -3% |
| AORTArtivion Inc. | $441M | 66% | 3.9% | 4%4y | 2% |
| MDXGMiMedx Group Inc | $419M | 84% | -0.3% | 34% | 8% |
| Group median | — | 72% | -15.1% | -8% | -4% |
The price
What a price has to assume.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Bioventus Inc. has delivered.
Bioventus Inc.’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.
Through the cycle, Bioventus Inc. earns about $37M on its 6.6% median owner-earnings margin. This year’s 12.7% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.
—
9.0% = the 4.71% 10-year Treasury (Aug 18, 2026) + 4.29 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.71%, as of Aug 18, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings $94M on 68M shares outstanding (a weighted basic average, the only count this filer tags); net debt $219M. The if-converted diluted count is 70M, 4% above the shares outstanding: the dilution overhang (convertibles, options) a buyer inherits. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← BV its page in the Manual BW →
Industry order: ← BSX the Medical Devices & Equipment chapter BWAY →